Bilirubin Total Gen.3 10421410190Recalls & reported problems
Roche Diagnostics GmbH · Class 2
All models of Bilirubin Total Gen.3 (4)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 07613336235508), received between Jul 15, 2025 and Jul 15, 2025 — classified as 1 malfunction.
The most frequently reported specific device problem is “High Test Results” (1 report).
2 other recalls cover devices cleared under the same FDA submission (K131544); they may or may not involve this specific model.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Reports received per month
Most reported problems
Device problems
- High Test Results1
Patient problems
- No Clinical Signs, Symptoms or Conditions1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
MalfunctionJul 15, 2025High Test Results; High Test Results
THERE WAS AN ALLEGATION OF QUESTIONABLE BILT3 BILIRUBIN TOTAL GEN.3 RESULTS FOR FOUR PATIENT SAMPLES ON A COBAS 6000 C (501) MODULE. PATIENT 1: THE INITIAL RESULT WAS 24.4 MG/DL, AND THE REPEATED RESULT WAS 1.4 MG/DL. PATIENT 2: ON (B)(6) 2025, THE INITIAL RESULT WAS 0.9 MG/DL, AND THE REPEATED RESULT WAS 2.4 MG/DL. PATIENT 3: ON (B)(6) 2025, THE INITIAL RESULT WAS 14.20 MG/DL, AND THE REPEATED RESULT WAS 0.7 MG/DL. PATIENT 4: ON (B)(6) 2025, THE INITIAL RESULT WAS 6.20 MG/DL, AND THE REPEATED RESULT WAS 0.3 MG/DL. THE SAMPLES WERE REPEATED BECAUSE THE PHYSICIAN QUESTIONED THE INITIAL RESULTS DUE TO THE RESULTS NOT MATCHING THE PATIENT'S CLINICAL HISTORY. THE REPEATED RESULTS WERE BELIEVED TO BE CORRECT.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 22511353 ↗
Recalls under the same FDA submission
These recalls involve devices cleared under K131544. One submission often covers many models, so check the product and lot details in each record.
- Z-0153-2020 · Sep 11, 2019 · TerminatedCobas c Bilirubin Total Gen.3 Catalog Number: 05795419190 - Product Usage: In vitro test for the quantitative determination of the total bilirubin in serum and plasma of adults an
- Z-1145-2019 · Dec 17, 2018 · TerminatedBilirubin Total Gen.3, Cat. Nos. 05795397190, 05795419190, 05795320160, 05795338160, 05795346160 ***added as of 5/10/19***05795397190, 05795648190 Product Usage: In vitro te
Other DIAZO COLORIMETRY, BILIRUBIN devices
- Dimension® Flex® reagent cartridge TBI 10444957Siemens Healthcare Diagnostics Inc. · DIAZO COLORIMETRY, BILIRUBIN2 recalls4 reports
- Dimension Vista® Flex® reagent cartridge TBIL 10445146Siemens Healthcare Diagnostics Inc. · DIAZO COLORIMETRY, BILIRUBIN1 recall7 reports
- VITROS 8383051Ortho-Clinical Diagnostics, Inc. · DIAZO COLORIMETRY, BILIRUBIN1 recall5 reports
- VITROS 1612365Ortho-Clinical Diagnostics, Inc. · DIAZO COLORIMETRY, BILIRUBIN1 recall1 report
- ARCHITECT 6L45-21Abbott Laboratories · DIAZO COLORIMETRY, BILIRUBIN46 reports
- ARCHITECT 6L45-22Abbott GmbH · DIAZO COLORIMETRY, BILIRUBIN30 reports
- ARCHITECT 6L45-41Abbott Laboratories · DIAZO COLORIMETRY, BILIRUBIN18 reports
- Bilirubin Direct Gen.2 08056951190Roche Diagnostics GmbH · DIAZO COLORIMETRY, BILIRUBIN17 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page